Morepen Laboratories
BSE 500288
4 stories, newest first.
- Analysts gave a short-term target and hold recommendation for Morepen Laboratories ahead of its results
- Board meeting on 27 October 2026 to consider Q2 and H1 FY27 results
- High Court quashes GST show cause notice seeking ₹117.94 crore recovery
- First U.S. ANDA submitted to USFDA for Sitagliptin Tablets in three strengths
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.